PURETECH HEALTH PLC - ADR (PRTC) Stock Price & Overview
NASDAQ:PRTC • US7462371060
Current stock price
The current stock price of PRTC is 15.89 USD. Today PRTC is down by -2.22%. In the past month the price decreased by -9.97%. In the past year, price decreased by -11.48%.
PRTC Key Statistics
- Market Cap
- 384.036M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.27
- Dividend Yield
- N/A
PRTC Stock Performance
PRTC Stock Chart
PRTC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PRTC. When comparing the yearly performance of all stocks, PRTC is a bad performer in the overall market: 76.38% of all stocks are doing better.
PRTC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRTC. The financial health of PRTC is average, but there are quite some concerns on its profitability.
PRTC Earnings
PRTC Forecast & Estimates
5 analysts have analysed PRTC and the average price target is 70.07 USD. This implies a price increase of 340.97% is expected in the next year compared to the current price of 15.89.
For the next year, analysts expect an EPS growth of -40.93% and a revenue growth -100% for PRTC
PRTC Groups
Sector & Classification
PRTC Financial Highlights
Over the last trailing twelve months PRTC reported a non-GAAP Earnings per Share(EPS) of -4.27. The EPS increased by 168.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 792.96% | ||
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| Debt/Equity | 0.05 |
PRTC Ownership
PRTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRTC
Company Profile
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Company Info
IPO: 2015-06-19
PURETECH HEALTH PLC - ADR
6 Tide Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Daphne Zohar
Employees: 56
Phone: 16174822333
PURETECH HEALTH PLC - ADR / PRTC FAQ
Can you describe the business of PURETECH HEALTH PLC - ADR?
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Can you provide the latest stock price for PURETECH HEALTH PLC - ADR?
The current stock price of PRTC is 15.89 USD. The price decreased by -2.22% in the last trading session.
What is the dividend status of PURETECH HEALTH PLC - ADR?
PRTC does not pay a dividend.
What is the ChartMill rating of PURETECH HEALTH PLC - ADR stock?
PRTC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about PURETECH HEALTH PLC - ADR (PRTC) stock?
5 analysts have analysed PRTC and the average price target is 70.07 USD. This implies a price increase of 340.97% is expected in the next year compared to the current price of 15.89.
How many employees does PURETECH HEALTH PLC - ADR have?
PURETECH HEALTH PLC - ADR (PRTC) currently has 56 employees.
What is the market capitalization of PRTC stock?
PURETECH HEALTH PLC - ADR (PRTC) has a market capitalization of 384.04M USD. This makes PRTC a Small Cap stock.